Cue Biopharma presenting data on lead clinical asset CUE-101 at symposium

Cue Biopharma announced that the company’s lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating in the CUE-101 clinical trial. The symposium is being held in Phoenix, Arizona and virtually from February 29 – March 2, 2024. Dr. Colevas will discuss previously presented data from the company’s ongoing Phase 1 trial evaluating CUE-101, as a monotherapy and in combination with KEYTRUDA for patients with recurrent/metastatic HPV+ head and neck squamous cell carcinoma. Data highlights include an overall response rate of 47% in first line patients treated with CUE-101 and pembrolizumab, compared to the historical ORR of 19% reported in the KEYNOTE-48 trial. In second line and beyond patients treated with CUE-101 monotherapy, the reported median overall survival was 20.8 months, compared to a mOS of approximately eight months reported in the KEYNOTE-40 trial. “Preliminary data of CUE-101 in combination with immunotherapy has been really promising with a much higher response rate than we would expect from immunotherapy alone, and a very tolerable side effect profile”, stated Dr. Colevas.